Effect of Menopause Hormone Therapy In Postmenopausal Women With CSVD And MCI
A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 328 participants.
Also called NCT05982470
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 328 participants
- Sponsor
- Registry
-
NCT05982470
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Unknown status
Technical summary
Registry record NCT05982470. Randomized; quadruple masking; primary purpose treatment. Start 2023-08-18 (anticipated); primary completion 2025-06-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effect of Menopause Hormone Therapy In Postmenopausal Women With CSVD And MCI
- Acronym
- MIRACLE
- Condition
- Cerebral Small Vessel Diseases
- Condition
- Postmenopausal Symptoms
- Condition
- Mild Cognitive Impairment
- Condition
- White Matter Hyperintensity
- Intervention (Drug)
- Estradiol Gel
- Intervention (Drug)
- Estradiol Placebo Gel
- Intervention (Drug)
- Progesterone Soft Capsule
- Intervention (Drug)
- Progesterone Placebo Soft Capsule
- Lead sponsor
- Beijing Tiantan Hospital
Record details
- Record id
cardio:ct-nct05982470- Content hash
42eacdd34aa3b527406c266286256d35f768f23e832f8fad79ce725e64872c1b